Susan Halabi
Halabi, Susan
VIAF ID: 276878286 (Personal)
Permalink: http://viaf.org/viaf/276878286
Preferred Forms
-
- 100 1 _ ‡a Halabi, Susan
-
-
- 100 1 _ ‡a Halabi, Susan
- 100 1 _ ‡a Halabi, Susan
- 100 0 _ ‡a Susan Halabi
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Confusion about mammography: prevalence and consequences. | |
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update | |
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). | |
Effects of a mammography decision-making intervention at 12 and 24 months. | |
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting | |
Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia | |
Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease. | |
Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. | |
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | |
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. | |
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer | |
Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes | |
High Dimensional Variable Selection with Error Control | |
Hospital visitors as controls | |
Identification of a Genomic Region between and Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) | |
Identification of women at increased risk for breast cancer in a population-based screening program | |
The impact of abnormal mammograms on psychosocial outcomes and subsequent screening | |
The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials | |
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy. | |
The importance of identifying and validating prognostic factors in oncology. | |
Independent data monitoring committees: an update and overview | |
Low incidence of familial breast cancer among Hispanic women | |
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. | |
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series | |
Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quit. | |
Menopausal hormones and risk of ovarian cancer | |
Mercury hair levels and factors that influence exposure for residents of Huancavelica, Peru. | |
On model specification and selection of the Cox proportional hazards model. | |
On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve | |
Oncology clinical trials, c2010: | |
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States) | |
Perception of consanguineous marriages and their genetic effects among a sample of couples from beirut | |
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy | |
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. | |
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. | |
Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. | |
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. | |
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 | |
Prognostic factors in early-onset epithelial ovarian cancer: a population-based study | |
Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480 | |
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study | |
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | |
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | |
Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools | |
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. | |
Reliability and validity of self and proxy reporting of morbidity data: a case study from Beirut, Lebanon | |
Reply to B. Rini et al and S. Buti et al. | |
Reply to F. Valcamonico et al. | |
Reply to M A Khattak et al. | |
Residential metal contamination and potential health risks of exposure in adobe brick houses in Potosí, Bolivia. | |
Sample size determination for comparing several survival curves with unequal allocations. | |
Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome. | |
Score and deviance residuals based on the full likelihood approach in survival analysis | |
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. | |
Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer. | |
A tailored intervention to aid decision-making about hormone replacement therapy | |
The Texas Breast Screening Project: Part II. Demographics, risk profiles, and health practices of participants. | |
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. | |
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. | |
Validation of a breast cancer risk assessment model in women with a positive family history. |